Arcus Biosciences, Inc.
NYSE:RCUSBiotechnology
-$0.09 today
- Market cap
- $2.27B
- Beta
- 0.84
- P/E (TTM)
- -8.2
- EPS (TTM)
- -$2.94
Volume 1.97M
Average 1.17M
RCUS Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Arcus Biosciences, Inc.NYSE: RCUS
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $15M rose 0.0% year over year, ahead of the -6.0% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 21.1% from the prior quarter. Over 3 fiscal years it compounded at -2.6% a year.
Context
- Stock-based compensation amounted to 24.3% of revenue in FY2025, down 5.2 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +0.0% holds above the trailing-twelve-month pace of -6.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 60M USD
- Year-over-year change
- -21.1%
- 4-year CAGR
- +2.2%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 60M | -21.1% |
| FY2024 | 2024-12-31 | 76M | +4.1% |
| FY2023 | 2023-12-31 | 73M | +12.3% |
| FY2022 | 2022-12-31 | 65M | +18.2% |
| FY2021 | 2021-12-31 | 55M | — |
Stock-Based Compensation vs competitors
How RCUS compares with its peers on the latest reported figures
- RCUS's LTM Jun 2026 stock-based compensation of $63M is the 2nd largest of the 9 companies compared; the peer median is $54.28M.
- Its year-over-year change of -6.0% is the 7th highest of 9, against a peer median of +37.0%.
- Stock-based compensation amounts to 53.8% of revenue for RCUS, versus a peer median of 75.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $69.95M | +39.2% | -0.1% | 1941.0% | |
| LTM Jun 2026 | $63M | -6.0% | -2.6% | 53.8% | |
| LTM Jun 2026 | $60.37M | +50.7% | +35.9% | — | |
| LTM Mar 2026 | $56.73M | +26.2% | +2.2% | 85.9% | |
| LTM Jun 2026 | $54.95M | +126.3% | +46.9% | 12.2% | |
| LTM Jun 2026 | $53.61M | +38.3% | +30.9% | 75.4% | |
| LTM Mar 2026 | $48.31M | +35.8% | +36.5% | 92.8% | |
| LTM Sep 2026 | $34.15M | -8.0% | -2.9% | 18.7% | |
| LTM Jun 2026 | $12.73M | -111.5% | +3.8% | 8.2% | |
| Peer median (excluding RCUS) | $54.28M | +37.0% | +17.3% | 75.4% | |
Competitors are the stored peer set for RCUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 52.83M | (267M) | (307M) | (283M) | (353M) |
| Depreciation & Amortization | 4M | 6M | 8M | 10M | 10M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 55M | 65M | 73M | 76M | 60M |
| Change in Working Capital | (375.62M) | 623M | (71M) | 22M | (194M) |
| Accounts Receivables | (17.05M) | 704M | 15M | 28M | 9M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.77M) | 8M | (1M) | 3M | 24M |
| Other Working Capital | (353.8M) | (89M) | (85M) | (9M) | (227M) |
| Other Non-Cash Items | 7.62M | 11M | (9M) | 5M | (5M) |
| Operating Cash Flow | (256.17M) | 438M | (306M) | (170M) | (482M) |
| Capital Expenditures | (26.08M) | (6M) | (24M) | (6M) | (2M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (718.87M) | (1.24B) | (788M) | (1.04B) | (1.08B) |
| Sales of Investments | 741.08M | 837M | 1.01B | 965M | 1.14B |
| Other Investing Activities | 0 | (3M) | 0 | 0 | 0 |
| Investing Cash Flow | (3.87M) | (413M) | 194M | (84M) | 66M |
| Debt Repayment | 5M | 0 | 0 | 47M | 49M |
| Common Stock Issued | 232.35M | 23M | 25M | 228M | 439M |
| Common Stock Repurchased | (6K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 10M | 8M | 2M | 0 |
| Financing Cash Flow | 237.34M | 33M | 33M | 277M | 488M |
| Effect of Forex Changes | (2.8M) | 0 | 0 | 0 | 0 |
| Net Change in Cash | (25.5M) | 58M | (79M) | 23M | 72M |
| Free Cash Flow | (282.25M) | 432M | (330M) | (176M) | (484M) |
Arcus Biosciences, Inc.
NYSE:RCUS
Intrinsic Alpha fair value
Locked
Current Price
$15.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.